Drug intelligence / Profile preview

triptorelin + estradiol valerate + micronized vaginal progesterone

Development stage: Preclinical
Lead developer: Debiopharm
Modality: Small Molecules
Administration: Intramuscular, Subcutaneous, Oral, Vaginal

Overview

This is a combination therapy consisting of triptorelin (a GnRH agonist), estradiol valerate (an estrogen prodrug), and micronized vaginal progesterone. Triptorelin acts on the pituitary gland to regulate hormone production. Estradiol valerate is a prodrug of estradiol that provides estrogen replacement. Micronized vaginal progesterone provides localized progesterone delivery. This combination may be used in fertility treatments, assisted reproductive technology protocols, or hormone therapy regimens.

Targets

PR (Progesterone receptor)GnRHR (Gonadotropin-releasing hormone receptor)ESR2 (ERβ)ESR1 (ERα)

Beyond the preview

Go deeper on triptorelin + estradiol valerate + micronized vaginal progesterone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on triptorelin + estradiol valerate + micronized vaginal progesterone.

Explore the full profile